Trial Profile
A Phase II Study of Liposomial IrinoTecan (Nal-IRI) With 5-Fluorouracil, Levofolinic Acid and Oxaliplatin in Patients With Resectable Pancreatic Cancer "nITRo Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Nov 2023
Price :
$35
*
At a glance
- Drugs Fluorouracil (Primary) ; Irinotecan (Primary) ; Levofolinic acid (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms nITRo Trial
- 11 Nov 2023 Results evaluating the safety and the activity of NALIRIFOX in the perioperative treatment of patients with rPDAC published in the European Journal of Cancer
- 24 Oct 2023 Results evaluating survival and level of biomarkers in newly diagnosed rPDAC patients were presented at the 48th European Society for Medical Oncology Congress
- 28 Feb 2023 Status has been changed to completed, as per Results presented at the 2023 Gastrointestinal Cancers Symposium